CARs: Beyond T Cells and T Cell-Derived Signaling Domains

Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma

(2020) Hailey Kintz et al.   CELLULAR IMMUNOLOGY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cells expressing a chimeric‐PD1‐Dap10‐CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer

(2020) Geoffrey Parriott et al.   IMMUNOLOGY

An immunoproteomic approach to characterize the CAR interactome and signalosome

(2019) Maria C. Ramello et al.   Science Signaling

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

(2019) Jiang Lv et al.   Journal of Hematology & Oncology

A cetuximab-mediated suicide system in CAR-modified hematopoietic stem cells for cancer therapy

(2019) Roy L. Kao et al.   HUMAN GENE THERAPY

CD19 chimeric antigen receptor–redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide–derived dendritic cell vaccine in leukemia

(2019) MEIRONG WU et al.   CYTOTHERAPY

CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy

(2019) Benedetto Sacchetti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

NK cells: An attractive candidate for cancer therapy

(2019) Behnaz Valipour et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4‐Akt‐ERK signalling by inhibiting EGR1‐dependent transcription

(2019) Lei Chen et al.   PHYTOTHERAPY RESEARCH

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

(2019) Antoni Ribas et al.   NATURE MEDICINE

CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms

(2019) Emiliano Roselli et al.   BIODRUGS

The making and function of CAR cells

(2019) Maja Zabel et al.   IMMUNOLOGY LETTERS

In vitro elimination of EGFR‐overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab

(2019) Sara Caratelli et al.   INTERNATIONAL JOURNAL OF CANCER

CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximab

(2019) Roberto Arriga et al.   INTERNATIONAL JOURNAL OF CANCER

Structural basis of assembly of the human T cell receptor–CD3 complex

(2019) De Dong et al.   NATURE

Determinants of response and resistance to CAR T cell therapy

(2019) Stefanie Lesch et al.   SEMINARS IN CANCER BIOLOGY

Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR

(2018) Miguel-Angel Perales et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Posttransplant chimeric antigen receptor therapy

(2018) Melody Smith et al.   BLOOD

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

(2018) Ye Li et al.   Cell Stem Cell

Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race

(2018) Dennis C. Harrer et al.   HUMAN GENE THERAPY

Gamma-delta (γδ) T cells: friend or foe in cancer development?

(2018) Yijing Zhao et al.   Journal of Translational Medicine

CD28-ζ CAR T cells resist TGF-β repression through IL-2 signaling which can be mimicked by IL-7 and an engineered IL-7/IL-2Rβ autocrine loop

(2018) Viktória Golumba-Nagy et al.   MOLECULAR THERAPY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens

(2018) Mario Leonardo Squadrito et al.   NATURE METHODS

The market for chimeric antigen receptor T cell therapies

(2018) Amy Yip et al.   NATURE REVIEWS DRUG DISCOVERY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-T cells: the long and winding road to solid tumors

(2018) Maria Michela D’Aloia et al.   Cell Death & Disease

Chimeric antigen receptors that trigger phagocytosis

(2018) Meghan A Morrissey et al.   eLife

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity

(2018) Ludmila Danilova et al.   Cancer Immunology Research

Abstract 2563: Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies

(2018) Edwin J. Velazquez et al.   CANCER RESEARCH

In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas

(2018) Carlos A. Ramos et al.   MOLECULAR THERAPY

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

(2018) Alexander I. Salter et al.   Science Signaling

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

(2018) Felicitas Rataj et al.   BRITISH JOURNAL OF CANCER

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS)

(2018) Y. Zhao et al.   Clinical & Translational Oncology

M2b macrophage polarization and its roles in diseases

(2018) Le-xun Wang et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology

(2018) Keisuke Watanabe et al.   Frontiers in Immunology

The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment

(2018) Laura Agresta et al.   Frontiers in Immunology

Exploiting natural killer group 2D receptors for CAR T-cell therapy

(2017) Benjamin Demoulin et al.   Future Oncology

Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells

(2017) Stephan Klöß et al.   HUMAN GENE THERAPY

Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma

(2017) Adam Lynch et al.   IMMUNOLOGY

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor

(2017) Jonathan Fisher et al.   MOLECULAR THERAPY

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains

(2017) Leah Alabanza et al.   MOLECULAR THERAPY

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy

(2017) Dominique Bollino et al.   Translational Research

FDA Approves Second CAR T-cell Therapy

(2017)   Cancer Discovery

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy

(2017) Sarah M. Larson et al.   Human Vaccines & Immunotherapeutics

Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies

(2017) Maksim Mamonkin et al.   Cancer Immunology Research

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

(2017) Sara Caratelli et al.   Frontiers in Immunology

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

(2017) Saul J. Priceman et al.   OncoImmunology

Chimeric antigen receptor T cells targeting Fc   receptor selectively eliminate CLL cells while sparing healthy B cells

(2016) E. Faitschuk et al.   BLOOD

Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment

(2016) Peng Qu et al.   CANCER LETTERS

Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy

(2016) Hamid Reza Mirzaei et al.   CANCER LETTERS

Development of Engineered T Cells Expressing a Chimeric CD16-CD3  Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

(2016) H. Tanaka et al.   CLINICAL CANCER RESEARCH

CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling

(2016) Nicla Porciello et al.   CYTOKINE & GROWTH FACTOR REVIEWS

T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G–opsonized target cells

(2016) Maria Michela D'Aloia et al.   CYTOTHERAPY

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+T-cell differentiation

(2016) Bryan McQueen et al.   IMMUNOLOGY

Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer

(2016) Sourav Paul et al.   INTERNATIONAL JOURNAL OF CANCER

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells

(2016) R. Velmurugan et al.   MOLECULAR CANCER THERAPEUTICS

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer

(2016) Carmen S.M. Yong et al.   Oncotarget

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination

(2016) Anke Redeker et al.   Frontiers in Immunology

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity

(2015) Masato Muto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone

(2015) Christian Krug et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)

(2015) David H. Lawson et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8+ T cells

(2015) Emily Whitman et al.   MOLECULAR IMMUNOLOGY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

(2015) M. J. Frigault et al.   Cancer Immunology Research

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer

(2015) Béatrice Clémenceau et al.   Journal of Immunology Research

The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8+ T Cell Generation

(2015) Catherine Gottschalk et al.   Frontiers in Immunology

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

(2014) S. Guedan et al.   BLOOD

Serial Transfer of Single-Cell-Derived Immunocompetence Reveals Stemness of CD8+ Central Memory T Cells

(2014) Patricia Graef et al.   IMMUNITY

Regulation of Thymic NKT Cell Development by the B7-CD28 Costimulatory Pathway

(2014) J. A. Williams et al.   JOURNAL OF IMMUNOLOGY

Gene-modified hematopoietic stem cells for cancer immunotherapy

(2014) Sarah Larson et al.   Human Vaccines & Immunotherapeutics

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Gene-Modified Human  / -T Cells Expressing a Chimeric CD16-CD3  Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

(2014) F. Ochi et al.   Cancer Immunology Research

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

(2014) Rachel E Beard et al.   Journal for ImmunoTherapy of Cancer

Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment

(2014) Theerawut Chanmee et al.   Cancers

T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing

(2013) K. Kudo et al.   CANCER RESEARCH

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

The Weal and Woe of Costimulation in the Adoptive Therapy of Cancer with Chimeric Antigen Receptor (CAR)-Redirected T Cells

(2013) A. Hombach et al.   CURRENT MOLECULAR MEDICINE

Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy

(2013) Satiro Nakamura De Oliveira et al.   HUMAN GENE THERAPY

Hematopoietic stem cells for cancer immunotherapy

(2013) Eric Gschweng et al.   IMMUNOLOGICAL REVIEWS

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

(2013) Marco L. Davila et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells

(2013) T. Zhang et al.   JOURNAL OF IMMUNOLOGY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach

(2013) Connie P. M. Duong et al.   PLoS One

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disparate Individual Fates Compose Robust CD8+ T Cell Immunity

(2013) V. R. Buchholz et al.   SCIENCE

Heterogeneous Differentiation Patterns of Individual CD8+ T Cells

(2013) C. Gerlach et al.   SCIENCE

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation

(2012) Lena Oevermann et al.   Annals of the New York Academy of Sciences

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Non-catalytic tyrosine-phosphorylated receptors

(2012) Omer Dushek et al.   IMMUNOLOGICAL REVIEWS

Antitumor Activity of T Cells Generated from Lymph Nodes Draining the SEA-expressing Murine B16 Melanoma and Secondarily Activated with Dendritic Cells

(2012) Jiyun Yu et al.   International Journal of Biological Sciences

An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo

(2012) T. Zhang et al.   JOURNAL OF IMMUNOLOGY

Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection

(2012) Manfred Lehner et al.   PLoS One

NKG2D receptor regulates human effector T-cell cytokine production

(2011) A. Barber et al.   BLOOD

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Regulation of immune cell function and differentiation by the NKG2D receptor

(2011) Biljana Zafirova et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

(2010) Tolga Sutlu et al.   CYTOTHERAPY

Promoting angiogenesis within the tumor microenvironment: The secret life of murine lymphoid IL-17-producing γδ T cells

(2010) Bruno Silva-Santos   EUROPEAN JOURNAL OF IMMUNOLOGY

CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens

(2010) Kenichi Asano et al.   IMMUNITY

Interleukin 10 decreases MICA expression on melanoma cell surface

(2010) Antonio E Serrano et al.   IMMUNOLOGY AND CELL BIOLOGY

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

(2010) Caroline J Voskens et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3  Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex

(2010) J. S. Bridgeman et al.   JOURNAL OF IMMUNOLOGY

A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells

(2010) C. Berger et al.   JOURNAL OF MEDICAL PRIMATOLOGY

Raising the NKT cell family

(2010) Dale I Godfrey et al.   NATURE IMMUNOLOGY

Functional Dichotomy between NKG2D and CD28-Mediated Co-Stimulation in Human CD8+ T Cells

(2010) Kamalakannan Rajasekaran et al.   PLoS One

An Enigmatic Tail of CD28 Signaling

(2010) J. S. Boomer et al.   Cold Spring Harbor Perspectives in Biology

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells

(2009) Bianca Altvater et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

(2009) B. Altvater et al.   CLINICAL CANCER RESEARCH

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity

(2009) C. S. Hinrichs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impaired interferon signaling is a common immune defect in human cancer

(2009) R. J. Critchley-Thorne et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DAP10- and DAP12-associated receptors in innate immunity

(2008) Lewis L. Lanier   IMMUNOLOGICAL REVIEWS

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION

NKG2D ligands: key targets of the immune response

(2008) Segundo González et al.   TRENDS IN IMMUNOLOGY